Pharmacokinetics of isoniazid, rifampin,and pyrazinamide in children younger than two years of age with tuberculosis: Evidence for implementation of revised World Health Organization recommendations

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5560-5567

  Thee, S ^a,b   Seddon, J A ^b,c   Donald, P R ^b   Seifart, H I ^b   Werely, C J ^d   Hesseling, A C ^b   Rosenkranz, B ^b   Roll, S ^a   Magdorf, K ^a   Schaaf, H S ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BE TABS; COTRIMOXAZOLE; ISONIAZID; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PYRAZIDE; PYRAZINAMIDE; RIFAMPICIN; RIMCURE; RITONAVIR; STAVUDINE; UNCLASSIFIED DRUG;

ABDOMINAL INFECTION; ACETYLATOR PHENOTYPE; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; EXTRAPULMONARY TUBERCULOSIS; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LUNG TUBERCULOSIS; MALE; MAXIMUM PLASMA CONCENTRATION; MIXED INFECTION; NUTRITIONAL STATUS; OBSERVATIONAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TUBERCULOUS MENINGITIS; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; AREA UNDER CURVE; CHILD, PRESCHOOL; COINFECTION; FEMALE; HIV INFECTIONS; HUMANS; ISONIAZID; MALE; NUTRITIONAL STATUS; PRACTICE GUIDELINES AS TOPIC; PYRAZINAMIDE; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS, PULMONARY; WORLD HEALTH ORGANIZATION;

EID: 81555201905     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05429-11     Document Type: Article

References (46)

1. Acocella, G., G. Buniva, U. Flauto, and F. Nicolis. 1970. Absorption and elimination of the antibiotic rifampicin in newborns and children, p. 755-760. In Proceedings of the Sixth International Congress of Chemotherapy 1969. University of Tokyo Press, Tokyo, Japan.
2. Acocella, G., A. Nonis, G. Gialdroni-Grassi, and C. Grassi. 1988. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose study. Am. Rev. Respir. Dis. 138:882-885.
3. Advenier, C., A. Saint-Aubin, P. Scheinmann, and J. Paupe. 1981. The pharmacokinetics of isoniazid in children (author's transl). Rev. Fr. Mal. Respir. 9:365-374. (Pubitemid 12167874)
4. Alcorn, J., and P. J. McNamara. 2002. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin. Pharmacokinet. 41:959-998. (Pubitemid 35168438)
5. Bartelink, I. H., C. M. Rademaker, A. F. Schobben, and J. N. van den Anker. 2006. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin. Pharmacokinet. 45:1077-1097. (Pubitemid 44631388)
6. Blake, M. J., et al. 2006. Pharmacokinetics of rifapentine in children. Pediatr. Infect. Dis. J. 25:405-409.
7. Boulahbal, F., S. Khaled, H. Bouhassen, and D. Larbaoui. 1978. Absorption and urinary elimination of pyrazinamid administered alone or in combination with isoniazid and rifampicin. Arch. Inst. Pasteur Alger. 53:165-185. (Pubitemid 11022065)
8. Chideya, S., et al. 2009. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIVinfected cohort of adults with tuberculosis from Botswana. Clin. Infect. Dis. 48:1685-1694.
9. de Rautlin de la Roy, Y., A. Hoppeler, G. Creusot, and A. M. Brault. 1974. Rifampicin levels in the serum and cerebrospinal fluid in children. Arch. Fr. Pediatr. 31:477-488.
10. Donald, P. R., D. Maher, J. S. Maritz, and S. Qazi. 2006. Ethambutol dosage for the treatment of children: literature review and recommendations. Int. J. Tuberc. Lung Dis. 10:1318-1330. (Pubitemid 44929444)
11. Ellard, G. A. 1969. Absorption, metabolism and excretion of pyrazinamide in man. Tubercle 50:144-158.
12. Graham, S. M., et al. 2006. Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection. Antimicrob. Agents Chemother. 50:407-413. (Pubitemid 43190946)
13. Gupta, P., V. Roy, G. R. Sethi, and T. K. Mishra. 2008. Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses. Br. J. Clin. Pharmacol. 65:423-427. (Pubitemid 351316921)
14. Gurumurthy, P., et al. 2004. Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin. Infect. Dis. 38: 280-283. (Pubitemid 38113038)
15. Heifets, L. B., P. J. Lindholm-Levy, and M. Flory. 1991. Comparison of bacteriostatic and bactericidal activity of isoniazid and ethionamide against Mycobacterium avium and Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 143:268-270.
16. Hussels, H., U. Kroening, and K. Magdorf. 1973. Ethambutol and rifampicin serum levels in children: second report on the combined administration of ethambutol and rifampicin. Pneumonologie 149:31-38.
17. Kearns, G. L., et al. 2003. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349:1157-1167. (Pubitemid 37122329)
18. Kinzig-Schippers, M., et al. 2005. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob. Agents Chemother. 49:1733-1738. (Pubitemid 40631582)
19. Llorens, J., R. J. Serrano, and R. Sanchez. 1978. Pharmacodynamic interference between rifampicin and isoniazid. Chemotherapy 24:97-103. (Pubitemid 8251918)
20. McIlleron, H., et al. 2007. Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers. J. Antimicrob. Chemother. 60:1398-1401.
21. McIlleron, H., et al. 2009. Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines. Clin. Infect. Dis. 48:1547-1553.
22. Miller, S. A., D. D. Dykes, and H. F. Polesky. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16:1215.
23. Moore, D. P., H. S. Schaaf, J. Nuttall, and B. J. Marais. 2009. Childhood tuberculosis guidelines of the Southern African Society for Paediatric Infectious Diseases. South. Afr. J. Epidemiol. Infect. 29:57-68.
24. Mouton, R. P., H. Mattie, K. Swart, J. Kreukniet, and J. de Wael. 1979. Blood levels of rifampicin, desacetylrifampicin and isoniazid during combined therapy. J. Antimicrob. Chemother. 5:447-454. (Pubitemid 9242454)
25. Pariente-Khayat, A., et al. 1997. Isoniazid acetylation metabolic ratio during maturation in children. Clin. Pharmacol. Ther. 62:377-383. (Pubitemid 27475221)
26. Parkin, D. P., et al. 1997. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am. J. Respir. Crit. Care Med. 155:1717-1722. (Pubitemid 27216683)
27. Peloquin, C. 1992. Therapeutic drug monitoring: principles and applications in mycobacterial infections. Drug Ther. 22:31-36.
28. Peloquin, C. A. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169-2183. (Pubitemid 35252827)
29. Pinheiro, V. G., et al. 2006. Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis. Braz. J. Infect. Dis. 10:374-379. (Pubitemid 46585565)
30. Rey, E., et al. 2001. Isoniazid pharmacokinetics in children according to acetylator phenotype. Fundam. Clin. Pharmacol. 15:355-359. (Pubitemid 34037826)
31. Roy, V., U. Tekur, and K. Chopra. 1999. Pharmacokinetics of pyrazinamide in children suffering from pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 3:133-137. (Pubitemid 29151816)
32. Ruslami, R., et al. 2007. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob. Agents Chemother. 51:2546-2551. (Pubitemid 47047335)
33. Sarma, G. R., S. Kailasam, N. G. Nair, A. S. Narayana, and S. P. Tripathy. 1980. Effect of prednisolone and rifampin on isoniazid metabolism in slow and rapid inactivators of isoniazid. Antimicrob. Agents Chemother. 18:661-666. (Pubitemid 11164134)
34. Schaaf, H. S., et al. 2005. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch. Dis. Child. 90:614-618. (Pubitemid 40780724)
35. Schaaf, H. S., et al. 2009. Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. BMC Med. 7:19.
36. Seifart, H. I., W. L. Gent, D. P. Parkin, P. P. van Jaarsveld, and P. R. Donald. 1995. High-performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids. J. Chromatogr. B Biomed. Appl. 674:269-275. (Pubitemid 26005467)
37. Smith, P. J., J. van Dyk, and A. Fredericks. 1999. Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma. Int. J. Tuberc. Lung Dis. 3:S325-S328 (Discussion, S351-S352).
38. Thee, S., A. Detjen, D. Quarcoo, U. Wahn, and K. Magdorf. 2007. Ethambutol in paediatric tuberculosis: aspects of ethambutol serum concentration, efficacy and toxicity in children. Int. J. Tuberc. Lung Dis. 11:965-971. (Pubitemid 47425022)
39. Thee, S., A. Detjen, U. Wahn, and K. Magdorf. 2008. Pyrazinamide serum levels in childhood tuberculosis. Int. J. Tuberc. Lung Dis. 12:1099-1101.
40. Thee, S., A. Detjen, U. Wahn, and K. Magdorf. 2009. Rifampicin serum levels in childhood tuberculosis. Int. J. Tuberc. Lung Dis. 13:1106-1111.
41. Thee, S., A. A. Detjen, U. Wahn, and K. Magdorf. 2010. Isoniazid pharmacokinetic studies of the 1960s: considering a higher isoniazid dose in childhood tuberculosis. Scand. J. Infect. Dis. 42:294-298.
42. Venkatesan, K. 1992. Pharmacokinetic drug interactions with rifampicin. Clin. Pharmacokinet. 22:47-65.
43. WHO. 2011. Child growth standards. WHO, Geneva, Switzerland. http: //www.who.int/childgrowth/standards/weight-for-age/en/index.html.
44. WHO. September 2009, posting date. Dosing instructions for the use of currently available fixed-dose combination TB medicines for children. WHO, Geneva, Switzerland. www.who.int/entity/tb/challenges/interim-paediatric -fdc-dosing-instructions-sept09.pdf.
45. Zhu, M., et al. 2002. Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy 22:686-695. (Pubitemid 34596476)
46. Zhu, R., et al. 10 May 2011, posting date. The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. J. Clin. Pharmacol. [Epub ahead of print.] doi:10.1177/0091270011402826.